Apomorphine sublingual spray - Renown Pharma

Drug Profile

Apomorphine sublingual spray - Renown Pharma

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Renown Pharma
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Parkinson's disease

Most Recent Events

  • 10 May 2017 Chemical structure information added
  • 07 Mar 2017 Preregistration for Parkinson's disease in United Kingdom (Sublingual)
  • 07 Mar 2017 Pharmacokinetics and adverse event data from a phase I trial in Parkinson's disease released by Renown Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top